+100%

est. 2Y upside i

HealthcareSeries B

Africa's #1 healthcare technology provider.

Rank

#416

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity in Helium Health offers high potential upside but with significant uncertainty due to stale valuation and missing growth data.

Last updated: July 19, 2026

Bull (20%)+229%

Revenue grows 30% annually yielding $66M in 24 months; exit multiple expands to 5x (e.g., IPO window or category leadership). After 20% dilution, upside 229%.

Base (55%)+90%

Revenue $66M; exit multiple settles at 3x in line with typical healthtech comps. After 20% dilution, upside 89.5%.

Bear (25%)+20%

Revenue $66M; exit multiple compresses to 2x amid slowdown. After 20% dilution, upside 19.7%, still above total funding so no preference wipeout.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

134%

Total funding of $42.2M represents 44.7% of entry valuation, creating a large preference overhang that dilutes common scenarios.

Dilution Risk

high

The last round was over 3 years ago; it is likely the company will raise again within 24 months, adding 15-25% dilution.

Secondary Liquidity

none

No secondary market exists for Helium Health shares; liquidity will only occur via acquisition or IPO, likely 3+ years out.

Questions to Ask at the Interview

Strategic questions based on Helium Health's data — designed to show you've done your homework.

  • 1

    “What is your strategy to achieve and sustain 30%+ annual growth in a fragmented African healthcare market?”

  • 2

    “How do you plan to navigate regulatory differences across countries while scaling your product?”

  • 3

    “What are your expectations for the next fundraising round and its impact on employee equity dilution?”

Community

Valuation Sentiment

Our model estimates +100% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.